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Abstract
A549 xenografts were allowed to grow in nude mice to about 5 mm in diameter, then diets were changed to modified AIN-76
diets containing 19% wt/wt. fish oil (FO) or 20% wt./wt. com oil (CO). Ten days later dietary ferric citrate (0.3% wt./dry wt.)
was added and doxoribicin (DOX) treatment (3.6 mg/kg i.v. each of the 5 days for 18 days) commenced. Treatment with DOX
halted the growth of tumors in the CO fed mice. However, in those mice, which consumed FO or FO with ferric citrate,
treatment with DOX caused significant tumor regression. © 2000 Elsevier Science Ireland Ltd. All rights reserved.
Keywords: Polyunsaturated fatty acids; Fish oil; Doxorubicin; A549 lung cancers

1. Introduction
Doxrubicin (OOX) is commonly used as a component of the chemotherapy regimen for the treatment of
a wide variety of human cancers including adenocarcinomas, sarcomas, melanomas, leukemias, and
lymphomas [13]. We and others [9,14,15,25,26]
have proposed that use of polyunsaturated fatty
acids (PUPAs) prior to chemotherapy, may sensitize
cancers to the effects of a chemotherapeutic drug. In
vitro studies indicate that addition of PUFA from fish
oil, including eicosapentanoic and docasahexanoic
acids, to the culture media, did increase the efficacy
of the chemotherapeutic drug against different cancer
cell types including: ZR-75-1 breast [5,6], trans*Corresponding author. Tel.: + 1-210-567-3896; fax: + 1-210567-3803.
E-mail address: hardrnan@uthscsa.edu (W.E. Hardman)

formed rat fibroblasts [1], L1210 leukemic cells
[11], A549 lung, PC-3 prostate [5], THKE tumorigenic human kidney epithelial [19], and MDA-MB
231 breast cancer cells [14]. However, to date, in
vivo studies on dietary PUFAs in addition to
chemotherapy treatment have been limited to breast
cancer cell types. We wanted to see if the concept of
supplementation of the diet of xenograft bearing mice
with the fatty acids of fish oil would increase the
efficacy of treatment of other types of cancers.
In the study described in this brief report, human
A549 lung cancer cells were implanted subcutaneously (s.c.) on the backs of nude mice. The tumors
were allowed to grow to about 5 mm in diameter, then
the diet was changed to include 20% corn oil or 19%
fish oiV1% corn oil. The mice were fed the high oil
diets for ten days to allow substitution of the dietary
fatty acids into cellular membranes before treatments
were initiated. The treatment wao; DOX at 3.8 mglkg

0304-3835/00/$ - see front matter © 2000 Elsevier Science Ireland Ltd. All rights reserved.
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body weight i.v., once each five days with or without
ferric citrate dietary supplementation. The extra iron
was added to the diet with the idea that the iron would
serve as a prooxidant to add to the prooxidation potential of DOX. It was found that there was significant
tumor regression in the mice, which consumed fish oil
diets before and during DOX treatment but not in the
mice which consumed corn oil diets before and during
DOX treatment. To our knowledge, this is the first
report demonstrating that dietary fish oil can increase
the efficacy of a chemotherapeutic drug against a
human lung cancer xenograft.

2. Methods and materials
2.1. Tumor cells
A549 human lung cancer cells (American Type
Culture Collection, Rockville, MD) were cultured
for injection in nude mice. The culture medium was
an enriched Ll5:SMEM base media supplemented
with other factors as described previously [21].
2.2. Animals
Twenty-five male nude mice were allowed to acclimate for one week then were inoculated with tumor
cells. The mice were housed under aseptic conditions
(positive air pressure in a designated nude mouse
room, cages, bedding, water and food were sterilized,
cages had microisolator tops) in a temperature (24°C)
and light controlled (12 h light per day) room. All
mouse handling was carried out under a laminar
flow hood. Our Institutional Animal Care and Use
Committee approved all animal use and handling
before commencing the experiment. The animal care
facilities are accredited by the American Association
for the Accreditation of Laboratory Animal Care.

serum free media) were injected s.c. on the upper back
of each mouse.
The experimental design for the tumor bearing
mice is diagrammed in Fig. 1, day 0 is the day of
change to the high com oil or fish oil diets. Mice
were fed a regular mouse chow diet while the tumors
were allowed to grow to about 5-mm diameter. This
allowed the tumors to become established as growing
tumors in the host mice before onset of the experimental diets. The tumor bearing mice were then
divided into groups and placed on diets based on the
AIN-76A diet but modified to contain either 20% com
oil or 19% menhaden fish oil with 1% com oil.
Compositions of the experimental diets are listed in
Table I. One percent com oil was included in the fish
oil diet to prevent the complications of essential fatty
acid deficiency. Fifteen mice received the high com
oil diet and 10 mice received the high fish oil diet. The
mice were maintained on these diets for ten days to
allow substitution of cellular membrane fatty acids
before beginning treatment with DOX or DOX and
ferric citrate. The diets were prepared weekly, individual daily portions for each cage were packaged and
the packages were stored in sealed containers at
-20°C to suppress spontaneous lipid peroxidation.
The food was replaced daily to prevent consumption
of oxidized lipids.
Treatment, defined as DOX alone or OOX with
supplemental ferric citrate in the diet, was initiated
after ten days on the corn oil or fish oil diets. Supplemental ferric citrate wa<; added to the diet of five mice
on the fish oil diet and five mice on the corn oil diet, at
a rate of 0.3% of the dry weight of the food. An
untreated control group of five mice continued on
the com oil diet. DOX was obtained as Adriamycin
PFC (Pharmacia & Upjohn, Inc. Kalamazoo, MI)
(doxorubicin hydrochloride for injection, USP) at a
Experimental Design
Phase II

Phase I

Day 0

2.3. Experimental design
Cultured A549 cells were harvested, rinsed and
suspended in serum-free L15:SMEM culture medium.
Cells in suspension were counted using a hemocytometer and the cell count was adjusted to 108/ml.
The suspension was kept well mixed during the time
of injection. A549 cells (5 X 106 cells in 0.05 ml of

Day 14

5 inlce, fish oil, DOX
Mouse
chow
Tumor growth

Fig. l. Diagram of the experimental design.

Day ~8
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Table 1
Composition of the diet by weight percent (g/ 100 g of food)

147

of a prolate spheroid
V = 4/3 X 3.14 XU2 X W/2 XD/2

Com oil diet
Ingredient"
Com oil
Menhaden oil
Sugar
Casein
Cornstarch
AIN-76 vitamin mixb
AIN-76 mineral mixb
Choline bitartrate
oL-methionine
Cellulose
Total

20.0
27.9

232
17.4
l.l5
4.06
0.23
0.35
5.8
100.1

Composition of the diets by % calorie.v"
20.6
Protein
Carbohydrated
40.1
39.3
Fat

Energy content of
each diet (kcaJ/g)

4.52

Fish oil diet

1.0
19.0
27.9
23.2
17.4
1.15
4.06
0.23
0.35
5.8
100.1

20.6
40.1
39.3
4.52

• Diet components and chemicals- Purified high nitrogen casein,
pure com starch, Alphacel (non-nutritive bulk cellulose) AIN-76
vitamin mixture. AIN-76 mineral mixture and choline bitartrate
(99% pure) was obtained from ICN Nutritional Biochemicals,
Cleveland, OH. Imperial brand (Sugarland. TX.) extra fine pure
cane sugar and I 00% pure com oil (Wesson) was purchased locally.
oL-methionine (cell culture, M.W. 149.2), menhaden fish oil and
ferric citrate was purchased from Sigma, St. Louis, Missouri.
b a-Tocopherol is 0.02 g/100 g and ferric citrate (16-17% Fe3+)
is 0.02 g/100 g of the ba.~aJ diet.
• Caloric content is calculated at 4 kcal/g for protein and carbohydrate and 9 kcal/g for fat. The diet which included a prooxidant
(iron) had 0.3 g/100 g of ferric citrate (16-17% Fe3+) added to the
19% MOor 20% CO diet.
d The % of calories from carbohydrate include the calories from
sucrose, cornstarch and sucrose in the vitamin and mineral mix.

The width measurement was used as the depth of
the tumor. This shape was a good approximation of
the shape of the tumors.
The experiment was terminated 18 days after the
initiation of DOX treatment. The mice were anesthetized using a ketamine/S.A. rompun mixture (0.2 cm 3/
25 g weight, 1M) prepared by our Laboratory Animal
Resources veterinarian, then killed by cervical dislocation. Mice in the untreated group consuming com
oil and the group consuming corn oil and treated with
ferric citrate and DOX had to be killed early because
of the large tumor size.

2.4. Statistical analyses
The growth of the tumors wa..<; divided into two
phases: (1) phase I was defined as the 10 days during
consumption of the com oil or fish oil diets plus four
days for initiation of a response to the treatment, (2)
phase II, the final 14 days, was defined as the time of
response to the treatment. Regression analysis for
Phase II was started at day 14 rather than day 10
(the day of the first DOX injection), to allow time
for response to DOX treatment to be reflected in a
change in the tumor size. Linear regression analysis
was used to determine if the change in the mean tumor
size during Phase I or Phase II of the experiment
showed a significant linear regression and to determine the slope (rate of growth of the tumor) of each
linear regression. A significant positive slope indicated tumor growth, a significant negative slope indicated tumor regression and a non-significant slope
Growth of A549 kJng cancer llllllOgrafls In nude mice
;..DJglnnl~

concentration of 2 mg/ml in the sterile isotonic solution. The DOX was stored under refrigeration and
protected from light. A dose of 3.6 mg DOX/kg
body weight (about 0.05 mV 28 g mouse) was injected
into the lateral tail vein of the mice once each 5 days
(days 10, 15, 20 and 25 after initiation of diet as in Fig.
2).
Tumor lengths and widths and body weights were
measured three times weekly. Measurements were
entered directly into an Excel spreadsheet. Tumor
sizes were calculated using the formula for the volume

-()-Com oN (no DOXtreatmanl)

-+-Com ol and fentc citrate
-l!t:- Flsh Clil
...._ Fllh oil and ferric cllrale
-Q-Corn ol

5

10

15

20

25

30

Days after lnitiallon of fish oil ciet

Fig. 2. Effects of experimental diets and DOX on growth of A549
lung cancer xenografts in nude mice (complete details under statistical analyses in text (Section 2.4 ).
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indicated no growth. Slope analysis for differences
between the regression of the mean tumor volume
for each group during the first or second phase of
the study was performed by PRISM and INSTAT software (GraphPad Software, San Diego, CA) using the
general linear model procedure to generate an
ANOV A. The ANOV A indicated that differences
were present, thus a Tuk:ey's multiple comparisons
post test was conducted to determine differences
between the slopes of each pair of lines against the
null hypothesis that there was no difference between
the slopes. A P s 0.05 was used to indicate that there
was a significant difference between slopes of the
regression lines and that the tumor growth rates represented by the slopes were significantly different.

3. Results
3.1. Body weight change

Table 2 lists the mean change in body weight
between day 0 (initiation of the experimental diets)
and day 28 (termination) of the experiment for each
dietary group. The results of ANOV A of the body
weight indicate that there were no significant differences in the mean change in body weight due to the
diet or treatment of the mice. At this dose of DOX and
on these diets, all groups gained weight over the
course of the experiment. This indicates that the
mice tolerated the diets and treatments equally well.
There was no indication of diarrhea or gastric distress
in any of the mice.
Table 2
The mean change in body weights of the groups of mice from day 0
(day of change to com oil or fish oil diets) to day 20 of the experiment DOX was initiated on day 10 in all groups except the 'no
DOXgroup'
Final diet group (n
Com oil
Fish oil
Corn oil+ Fe
Fish oil+ Fe
Com oil; no DOX

= 5)

Mean (g) ±
+5.6:!:
+4.8:!:
+4.8 ±
+4.2:!:
+3.3:!:

so•

2.0
2.6
1.6
1.2
0.7

• ANOVA showed that there were no significant differences in
the change in body weight due to the diet or treatment of the mice.

3.2. Tumor growth

Fig. 2 is a graph of the mean tumor size over the
time of the experiment. Day 0 is the day that the diets
of the mice were changed to the high com oil or high
fish oil diets. The slope of the mean tumor size of each
group was determined between day 0 and day 14
(Phase I) and from day 14 to day 28 (Phase II). Slopes
of the linear regression for each group and result<; of
ANOVA are reported in Table 3. A summary of the
results of ANOV A and Tukey' s multiple comparisons
test of the tumor growth rates follows:
( l) There was not a significant difference in the rate
of growth of the tumor due to the diet composition
during phase I of the experiment, regardless of
whether the mice were consuming 20% corn oil
or 19% fish oil plus 1% com oil in the diet. Thus,
supplementation of the diet with fish oil did not
significantly alter growth of this tumor prior to
the treatment with DOX or DOX plus iron;
(2) The type of oil in the diet, however, did make a
significant difference in the efficacy of DOX treatment. Specifically, DOX halted the growth of the
tumors in the group of mice consuming com oil,
Table 3
Growth mte of A549 human lung tumors (mean mm 3 per day + SD
of slope)
Final diet/treatment group
(n = 5)

Phase I"

Phase II

Com oil; DOX
Fish oil; DOX
Com oil + iron; DOX
Fish oil + iron; DOX
Com oil; no DOX

14.8:!:
16.2 :!:
15.9 ±
11.2:!:
14.9:!:

-1.5
-11.1
34.1
-13.1
14.9

1.9
1.8
1.3
2.3
2.0

± 1.8h
:!: 1.5b
:!: 4.2b
± 4.2b
± 2.0h

• Linear regression analyses showed that during phase I. all
slopes were significantly different from 0. ANOVA of the slopes
showed that the growth mtes of the tumors (slopes) were not significantly different from each other during Phase I, when mice were
consuming either a com oil or a fish oil diet without added iron and
without DOX treatment.
b Linear regression analyses showed that the tumor growth rate(slope of the regression line) of the group of mice which consumed
com oil and was treated with DOX was not significantly different
from a slope of 0. The tumor growth rate of all other groups was a
significant positive or negative slope. ANOVA followed by Tukey' s
multiple comparisons test of the slopes showed that growth mtes
(slopes) with the same letter are not significantly different, growth
rates with different letters are significantly different.
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that is, the slope of the regression line for the
growth of these tumors was not significantly different from zero (a horizontal line indicates no growth
over the time of treatment). However, the tumors in
the mice consuming fish oil and being treated with
DOX significantly regressed, that is, the slope of
the linear regression line for this group was significantly negative;
(3) The type of oil in the diet made a significant
difference when the treatment was a combination of
supplemental iron and DOX. In the mice fed com
oil, the tumor continued to grow when the treatment
was iron and DOX. However, in the mice fed fish
oil, the tumors significantly regressed when the
treatment was iron and DOX.

4. Discussion
In this brief report, we provide evidence that the
efficacy of doxorubicin against A549 lung cancer
xenografts was significantly increased when the
AIN-76 diet formula (Table 1) was supplemented
with fish oil and that there were no observed harmful
side effects to the mice due to the consumption of fish
oil. There was some unavoidable variation in the
mean tumor size at the time of initiation of the diet.
However, as shown in Table 3, the tumor growth rate
of the group with the largest tumors (group 5) and of
the group with the smallest tumors (group 1), both fed
the com oil diet, were not significantly different indicating that mean tumor size at the time of the diet
change did not significantly alter the tumor growth
rate. The effect of consumption of fish oil in the diet
in the absence of DOX can be evaluated using the
portion of the tumor growth curve analyzed prior to
initiation of DOX treatment. There was no significant
difference in growth rates between the groups which
consumed com oil and those which consumed fish oil.
Thus, neither fish oil alone nor the differences in
tumor size at the time of diet change, significantly
altered the growth rate of this tumor model prior to
the initiation of DOX or DOX and iron treatment.
The data show that, in mice fed com oil, DOX
inhibited growth of, but did not cause regression of,
the tumors. This indicates that the tumor cells were
either growth arrested and/or that only a fraction of
the tumor cell population was killed by the DOX.
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However, DOX did not inhibit growth of tumors of
mice fed com oil with iron. A possible explanation for
these results is that in the presence of dietary com oil,
tumor cells that were not killed by OOX treatment had
their growth stimulated by the iron in the diet.
Unfortunately, we do not have adequate data to
evaluate how the fish oil worked to suppress tumor
growth. However, other reports do provide clues to
how fish oil works to increase the efficacy of DOX
chemotherapy. For example, increased lipid peroxidation in the tumor is one likely mechanism for the
increased efficacy of DOX following consumption
of fish oil. One mechanism of action for DOX is the
formation of DOX-metal complexes and the production of free radical complexes [13]. The results of a
number of reports show that membrane fatty acids of
normal tissues [7,18,23,24,26] and of tumors [7],
become more unsaturated when the mice consume
fatty acids from fish oil instead of com oil. Providing
the PUFA substrate in the cell membranes would be
expected to increase the generation of free radicals
and would be expected to increase the oxidative
damage from these free radicals. In fact, the increased
unsaturation of membrane lipids was associated with
increased lipid peroxidation and decreased tumor
growth in MDA-MB 231 xenografts treated with edelfosine (Hardman et al., unpublished results) or in MX1 xenografts treated with DOX compared to mice fed
com oil [26].
Other mechanisms have also been proposed to
account for the suppression of cancer growth by fish
oil or combinations of fish oil and a drug. These
mechanisms include:
( 1) Decreased levels of PGE2 following dietary fish
oil [16,28]. Decreased PG~ is associated with
increased immune activity [17] and decreased
tumor promotion and growth [12]~
(2) Decreased activity of protein kinase C (PKC),
which has been associated with reversal of drug
resistance [1OJ and slowed angiogenesis (reviewed
in [20]).

In addition, the n-3 fatty acids offish oil have been
shown to be beneficial to the patient by suppressing
cancer cachexia [3,4,22,27] and by improving the
response to radiotherapy [ 10]. Bougnoux et al. has
reported that an increased amount of n-3 fatty acids
in the composition of adipose tissue was associated

150

W.E. Hardman et al. I Cancer Letters 151 (2000) 145-151

with better response to chemotherapy in brea~t cancer
patients [8]. Atkinson et al. has reported that dietary
docosahexanoic acid (22:6n-3) slowed tumor growth
and enhanced bone marrow cellularity of mice
injected with fibrosarcoma cells [2]. Use of the n-3
fatty acids derived from fish oil as an adjuvant to
therapy has the potential to increase the efficacy of
the chemo- or X-radiation therapies in current use.
Our future studies will be designed to provide
adequate tumor tissue at sacrifice time to investigate
the mechanisms of n-3 fatty acids to increase the efficacy of cancer therapy. This information about the
mechanisms of action of n-3 fatty acids will allow
us to devise even more effective cancer treatment
strategies.
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